Monocarboxylate Transporter 8 Deficiency
1
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Egetis TherapeuticsSweden - Stockholm
2 programs1
TiratricolPhase 31 trial
TiratricolN/A1 trial
Active Trials
NCT05911399Available
Trial Timeline
Clinical trial activity over time
2023
2024
2025
2026
Egetis TherapeuticsTiratricol
Clinical Trials (2)
Withdrawal of Tiratricol Treatment in Males With Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency)
Start: Jul 2023Est. completion: Sep 2025
Phase 3Completed
Expanded Access Program for Tiratricol in Patients With Monocarboxylate Transporter 8 Deficiency
N/AAvailable
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space